Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Stock Report

| More

TGA, Australia announces Ranitidine test results

Posted On: 2019-10-23 16:58:47

Strides Pharma Science Limited (Strides or Company) today shared further updates regarding the supplies of its Ranitidine Tablets. The Company, on September 27, 2019, temporarily suspended the manufacturing and sale of its Ranitidine tablets for the US and Australia markets given the concerns around impurity called N-nitrosodimethylamine (NDMA) which is associated with an increased risk of cancer. As per European Medicines Agency (EMA), NDMA is present in some foods and in water supplies but is not expected to cause harm when ingested in very low levels3.

Summary of the announcement made by Therapeutic Goods Administration, Australia(TGA)1:

- The TGA Laboratories tested samples of Ranitidine medications available in the Australian market.

- A total of 135 batches from 10 Australian companies were tested for NDMA adapting the newly issued US Food and Drug Administration (USFDA) 2 test method using liquid chromatography with high resolution mass spectrometric detection(LC-HRMS).

- TGA has now taken a decision to recall all Ranitidine products with levels of NDMA at or above 0.3 ppm while all batches with levels below 0.3 ppm are available for sale.

Results from the TGA Laboratories Tests

- Out of the 135 batches of Ranitidine which were tested by TGA, 109 batches were found to have NDMA level at or above the acceptable limit of 0.3 ppm. These batches include 3 batches from Strides supplied to its Australian partner Arrow Pharma Pty Ltd(Arrow).

- Only 24 oral solid dosage batches were found to have levels of NDMA within the acceptable limit of 0.3 ppm of which 20 batches were manufactured by Strides for its partner Arrow with API supplied by Solara Active Pharma Sciences.

Next Steps for Australia

- At Strides, product quality and patient safety is of paramount importance, and we are confident of consistently meeting the acceptable limits of NDMA in Ranitidine.

- Batches manufactured by Strides are now available for sale in Australia through its partner Arrow.

Additional Update on US

- Strides has submitted all requested data to the USFDA in response to the Information Request received on Ranitidine.

- Strides is awaiting further feedback from the USFDA on the NDMA limits for Ranitidine.

Shares of Strides Pharma Science Ltd was last trading in BSE at Rs.342.05 as compared to the previous close of Rs. 350.65. The total number of shares traded during the day was 97027 in over 1664 trades.

The stock hit an intraday high of Rs. 353.75 and intraday low of 336.35. The net turnover during the day was Rs. 33295814.

Source: Equity Bulls

Click here to send ur comments or to

Other Headlines:

Blue Dart Express Sales at Rs. 31,664 million

Sun Pharma Advanced Research Company Ltd board to announce 4th quarter results on June 2, 2020

Stovec Industries Ltd board to consider Q4, FY20 results on June 4, 2020

Greaves Cotton Limited board to approve Q4, FY20 results on June 5, 2020

CRISIL reaffirms commercial papers rating of Edelweiss Financial Services Limited

Gulshan Polyols Ltd Q4 PAT at Rs. 2.78 crore

Alkem Laboratories Ltd Board to consider FY20 results & Final Dividend on June 05, 2020

Wonderla Holidays Ltd Q4 FY20 PAT slides to Rs. 1.56 crore

S H Kelkar and Company Ltd consolidated Q4 FY2020 PAT at Rs. 12.02 crore

Kewal Kiran Clothing Ltd posts Rs. 15.76 crore consolidated PAT in Q4 FY2020

Gujarat Gas Ltd board to consider FY20 results, dividend on June 5, 2020

Kewal Kiran Clothing Ltd Board approves Dividend of Rs. 6

Deepak Nitrite Ltd reports consolidated PAT of Rs. 172.30 crore in Q4 FY2020

Coromandel International Ltd board recommends dividend of Rs. 12 for FY2020

Fiinovation Partners with Dhampur Sugar to help Delhi Slums Fight COVID-19 Pandemic

LTI Wins 2020 SAP® Pinnacle Award as the Industry Innovation Partner of the Year

Kotak Mahindra Bank fixes floor price for QIP as Rs. 1147.75

Wipro launches Global Channel Partner Program for innovative products and platforms

Shanthi Gears Limited announces financial results for period ended March 31, 2020

V I P Industries Ltd reports consolidated Q4 FY20 PAT at Rs. 9.52 crore

Coromandel International Ltd Q4 FY20 consolidated net profit at Rs. 234.20 crore

PRAJ Industries Ltd posts Rs. 24.86 crore PAT in Q4 FY20

Visaka Industries Ltd reports Q4 PAT of Rs. 6.85 crore

Maruti Suzuki partners with ICICI bank to offer customers specially curated, flexible EMI financing schemes

ITI Limited manufactures face shields -Joins fight against COVID19

Sundaram Finance Ltd board to consider final dividend for FY20

Add-Shop Promotions Ltd Board approves 3:4 Bonus Issue

Satia Industries Limited Signs Agreement with Minerals Technologies to Construct a 42,000 Metric Ton Per Year Satellite PCC Plant in India

Vakrangee announces corporate agency tie up with LIC

Symphony Limited board to announce 4th quarter results on May 29, 2020

Firstsource Solutions Ltd Q4 FY20 consolidated PAT climbs QoQ to Rs. 91.57 crore

Automotive Axles Ltd posts PAT of Rs. 5.75 crore in Q4

Daawat Basmati Rice celebrates relationships with # PehliDaawat Campaign

Newgen Software Technologies Ltd Board approves dividend of Rs. 2 for FY20

Automotive Axles Ltd board recommends dividend of Rs. 0.80

Newgen Software Technologies Ltd Q4 FY20 consolidated PAT up QoQ at Rs. 41.46 crore

McDonald's India Introduces Contactless Take-Out Service For Customers

Infosys and Avaloq Partner to Strengthen Wealth Management Capabilities through Digital Platforms

Reliance Power wins lawsuit in Indonesian Court, to get arbitration award of $68 million

Menon Bearings Ltd Q4 PAT at Rs. 3.30 crore

Indoco receives USFDA approval for Succinylcholine Chloride Injection USP

Steel Strips Wheels Ltd's tractor segment production running at 90% capacity

Orient Electric Ltd board to announce Q4, FY20 results, final dividend on June 1, 2020

Customer Safety in focus: Maruti Suzuki issues safety norms for True Value

Glenmark to commence another new Phase 3 clinical trial on a combination of two anti-viral drugs Favipiravir and Umifenovir in hospitalized patients of moderate COVID-19 in India

Zuari Agro Chemicals Ltd's NPK-A plant resumes operation from May 25, 2020

Polyplex Corporation Ltd Q4 FY2020 consolidated PAT falls to Rs. 22.97 crore

InterGlobe Aviation Ltd board to consider Q4, FY20 results on June 2, 2020

Jubilant Life Sciences Ltd board to approve FY20 results, NCD issue on May 29, 2020

Polyplex Corporation Ltd Board approves final dividend of Rs. 6

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019